Implications of occult metastatic cells for systemic cancer treatment in patients with breast or gastrointestinal cancer

Seminars in Surgical Oncology

Volumn 20, Issue 4, 2001, Pages 334-346

  Braun, Stephan ^a   Rosenberg, Robert ^a   Thorban, Stefan ^a   Harbeck, Nadia ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Adjuvant therapy; Antibody therapy; Bone marrow; Breast cancer; Colorectal cancer; Cytokeratin; Gastric cancer; Lymph nodes; Oesophageal cancer; Pancreatic cancer; Peripheral blood; Prognosis; Survival

Indexed keywords

ANTHRACYCLINE; CARBOPLATIN; CELL MEMBRANE PROTEIN; CLODRONIC ACID; CYTOKERATIN; EDRECOLOMAB; EPIRUBICIN; IFOSFAMIDE; MONOCLONAL ANTIBODY; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB; VINBLASTINE;

BONE MARROW BIOPSY; BONE MARROW METASTASIS; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DIGESTIVE SYSTEM CANCER; HUMAN; IMMUNOCYTOCHEMISTRY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TUMOR CELL;

BONE MARROW NEOPLASMS; BREAST NEOPLASMS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0034756165     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/ssu.1052     Document Type: Review

References (123)

1. Development of donor-derived prostate cancer in a recipient following orthotopic heart transplantation
2. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells
3. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II or III breast cancer
4. Micrometastases in breast cancer: Long-term follow-up of the first patient cohort
5. Increased detection of mammary carcinoma cells in marrow smears using antisera to epithelial membrane antigen
6. Detection of micrometases in patients with primary breast cancer
7. Meta-analysis of studies on bone marrow micrometastases: An independent prognostic impact remains to be substantiated
8. Comparative analysis of micrometastasis to the bone marrow and lymph nodes of nodenegative breast cancer patients receiving no adjuvant therapy
9. Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors
10. Outcome of primary-breastcancer patients with micrometastases: A long-term follow-up
11. Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: Results of a 20-year median follow-up
12. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
13. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up
14. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases
15. Epithelial tumour cells in bone marrow of patients with pancreatic carcinoma detected by immunocytochemical staining
16. Oesophageal cancer: Prognostic significance and therapeutic consequences of individual tumour cells in lymph nodes
17. Micrometastasis and tumour cell microinvolvement of lymph nodes from oesophageal squamous cell carcinoma
18. Micrometastatic tumor cells in bone marrow of patients with gastric cancer: Methodological aspects of detection and prognostic significance
19. Prognostic significance of bone marrow micrometastases in patients with gastric cancer
20. Clinical significance of occult micrometastasis in lymph nodes from patients with early gastric cancer who died of recurrence
21. Frequency and clinical impact of lymph node micrometastasis and tumour cell microinvolvement in patients with adenocarcinoma of the esophagogastric junction
22. Early lymphatic tumour cell dissemination in pancreatic cancer: Frequency and prognostic significance
23. Micrometastases in bone marrow: Prognostic indicators for pancreatic cancer
24. Disseminated tumour cells in pancreatic cancer patients detected by immunocytology: A new prognostic factor
25. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients
26. Micrometastases and survival in stage II colorectal cancer
27. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection
28. P53 mutations in primary and metastatic tumors and circulating tumor cells from colorectal carcinoma patients
29. Detection of cytokeratin 18-positive cells in bone marrow of breast cancer patients: No prediction of bad outcome
30. Bone marrow micrometastases in 109 breast cancer patients: Correlations with clinical and pathological features
31. Comparative analyses of bone marrow micrometastases in breast and gastric cancer
32. Monoclonal antibody LICR-LON-M8 does not predict the outcome of operable breast cancer
33. Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients
34. Immunohistochemical staining of bone marrow biopsies for detection of occult metastasis in breast cancer
35. Use of monoclonal antibody MBr1 to detect micrometastases in bone marrow specimens of breast cancer patients
36. Monoclonal antibody detection of carcinoma cells in bone marrow biopsy specimens from breast cancer patients
37. Molecular metastases in stage I pancreatic cancer: Improved survival with adjuvant chemoradiation
38. Impact of cytokeratin20 and carcinoembryonic antigen mRNA detection by RT-PCR in regional lymph nodes of patients with colorectal cancer
39. Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow
40. Dissemination of tumour cells in patients undergoing surgery for colorectal cancer
41. Detection of micrometastases in histologically negative lymph nodes in oesophageal cancer
42. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow
43. Cytomorphology and cell yield in a new cytocentrifugal technique allowing the collection of the cell-free supernatant
44. Incidence and histopathology of metastases of mammary carcinoma in biopsies from the posterior iliac crest
45. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies
46. Epithelial tumor cells in bone marrow of patients with colorectal cancer: Immunocytochemical detection, phenotypic characterization, and prognostic significance
47. Monoclonal antibodies to epithelial membrane antigen and human milk fat globule mucin define epitopes expressed on other molecules
48. A new monoclonal antibody to epithelial membrane antigen (EMA)-E29. A new comparison of its immunocytochemical reactivity with polyclonal anti-EMA antibodies and with another monoclonal antibody, HMFG-2
49. Human lymphoid cells express epithelial membrane antigen
50. Detection and management of bone marrow micrometastases in breast cancer
51. Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
52. Expression of MUCl epitopes on normal bone marrow: Implications for the detection of micrometastatic tumor cells
53. The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis
54. The dissemination of subcutaneously inoculated tumor cell suspensions
55. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
56. Occult axillary lymph node metastases in "node-negative" breast carcinoma
57. Prognostic significance of breast cancer axillary lymph node micrometastases assessed by two special techniques: Reevaluation with longer follow up
58. Prognostic importance of occult axillary lymph node micrometastases from breast cancers
59. The immunohistochemical detection of lymph node metastases from infiltrating lobular carcinoma
60. Occult axillary node metastases in breast cancer: Their detection and prognostic significance
61. Detection of circulating mammary carcinoma cells in the peripheral blood of breast cancer patients via a nested reverse transcriptase polymerase chain reaction assay for mammaglobin mRNA
62. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer
63. Evaluation of breast tumour cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA
64. Clinical significance of bone marrow metastases as detected using polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation
65. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction
66. Keratin 19 mRNA measurement to detect micrometastases in lymph nodes in breast cancer patients
67. The detection of breast cancer micrometastases in axillary lymph nodes by means of reverse transcriptase-polymerase chain reaction
68. Monitoring of tumor cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: Comparison of immunocytochemical tumor cell staining and reverse transcriptase-polymerase chain reaction
69. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients
70. Limitations of reverse transcriptase-polymerase chain reaction for detection of micrometastatic epithelial cancer cells in bone marrow
71. Detection of breast cancer micrometastases in axillary lymph nodes by using polymerase chain reaction
72. Immunocytochemical detection of disseminated tumor cells in the bone marrow of patients with esophageal carcinoma
73. Prognostic value of immunohistochemically identifiable tumour cells in lymph nodes of patients with completely resected oesophageal cancer
74. Malignant potential and cytogenetic characteristics of occult disseminated tumor cells in esophageal cancer
75. Micrometastases in oesophagogastric cancer: High detection rate in resected rib segments
76. Immunohistochemical evaluation of lymph node micrometastases from gastric carcinomas
77. Cytokeratin-positive tumor cells in bone marrow for identifying distant micrometastasis of gastric cancer
78. Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer
79. Association of tumor angiogenesis with bone marrow micrometastases in breast cancer
80. Urokinase plasminogen activator receptor (uPA-R): One potential characteristic of metastatic phenotypes in minimal residual tumor disease
81. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer
82. Immunocytochemically detected free peritoneal tumour cells are a strong prognostic factor in gastric carcinoma
83. Isolated tumor cells are frequently detectable in the peritoneal cavity of gastric and colorectal cancer patients and serve as a new prognostic marker
84. Immunocytological detection of micrometastatic cells: Comparative evaluation of findings in the peritoneal cavity and the bone marrow of gastric, colorectal and pancreatic cancer patients
85. Clinical application of K-ras oncogene mutations in pancreatic carcinoma: Detection of micrometastases
86. Spread of colorectal cancer micrometasases in regional lymph nodes by reverse transcriptase-polymerase chain reactions for carcinoembryonic antigen and cytokeratin 20
87. Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcriptase-polymerase chain reaction in patients with gastrointestinal or breast carcinomas
88. Polychemotherapy for early breast cancer: An overview of the randomised trials
89. An overview of adjuvant therapy for colorectal cancer
90. Rationale for adjuvant chemotherapy
91. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells
92. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients
93. Adoptive immunotherapy with monoclonal antibody 17-1A to reduce minimal residual disease in breast cancer patients after high-dose chemotherapy
94. Persistence of isolated tumor cells in patients with breast cancer after sequential high-dose therapy with peripheral blood stem cell transplantation
95. Monoclonal antibody therapy with edrecolomab in breast cancer patients: Monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow
96. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2 overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
97. Phase II study of weekly intravenous recombinant humanized anti-p185Her2 monoclonal antibody in patients with Her2/neu-overexpressing metastatic breast cancer
98. Phase I trial of murine monoclonal antibody L6 in breast, colon, ovarian, and lung cancer
99. Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer
100. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial
101. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma
102. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma - Long-lasting, complete remissions can be induced
103. Induction of specific immunity to human colon carcinoma by anti-idiotypic antibodies to monoclonal antibody CO17-1A
104. Specific detection of anti-idiotypic immune responses in cancer patients treated with murine monoclonal antibody
105. Radioimmunodetection of cancer with the use of indium-111-labeled monoclonal antibodies
106. Antibody-based immunological therapies
107. Monoclonal antibodies in the detection and therapy of micrometastatic epithelial cancer
108. Delivery of molecular medicine to solid tumors
109. The epithelial cell surface antigen 17-1A, a target for antibody -mediated tumor therapy: Its biochemical nature, tissue distribution and recognition by different monoclonal antibodies
110. Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumours
111. Biological activity in the human system of isotype variants of oligosaccharide Y-specific murine monoclonal antibodies
112. Tumor antigen heterogeneity of disseminated breast cancer cells: Implications for immunotherapy of minimal residual disease
113. Cancer genes: Complexes and complexities
114. Growth dominance of the metastatic cancer cell: Cellular and molecular aspects
115. p53 immunostaining of megakaryocytes is preferentially observed in patients with epithelial malignancies
116. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumor cells
117. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastatic carcinoma cells
118. Detection, characterization and tumorigenicity of tumor cells in human bone marrow
119. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
120. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms
121. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice
122. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness
123. Immunomagnetic enrichment of disseminated tumor cells from bone marrow of carcinoma patients